Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.03)
# 3,037
Out of 5,126 analysts
40
Total ratings
41.67%
Success rate
-4.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Outperform | $232 → $228 | $223.43 | +2.05% | 6 | Feb 5, 2026 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $38 → $36 | $16.80 | +114.29% | 1 | Dec 15, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $89 → $94 | $100.47 | -6.44% | 4 | Dec 9, 2025 | |
| VERA Vera Therapeutics | Maintains: Outperform | $75 → $97 | $43.50 | +122.99% | 1 | Dec 8, 2025 | |
| EVMN Evommune | Initiates: Outperform | $40 | $17.31 | +131.08% | 1 | Dec 1, 2025 | |
| FBRX Forte Biosciences | Initiates: Outperform | $65 | $27.59 | +135.59% | 1 | Nov 25, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $775 → $910 | $811.45 | +12.14% | 5 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $20 → $14 | $1.35 | +937.04% | 4 | Sep 22, 2025 | |
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $1.50 | +233.33% | 1 | Apr 29, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $2.51 | +139.04% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $179 → $170 | $18.50 | +818.92% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $5.68 | +252.11% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $201 → $206 | $272.74 | -24.47% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $3.57 | +516.25% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $1.82 | +449.45% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $83.91 | -28.49% | 1 | Oct 5, 2022 |
AbbVie
Feb 5, 2026
Maintains: Outperform
Price Target: $232 → $228
Current: $223.43
Upside: +2.05%
Dyne Therapeutics
Dec 15, 2025
Maintains: Outperform
Price Target: $38 → $36
Current: $16.80
Upside: +114.29%
Mirum Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $89 → $94
Current: $100.47
Upside: -6.44%
Vera Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $75 → $97
Current: $43.50
Upside: +122.99%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $17.31
Upside: +131.08%
Forte Biosciences
Nov 25, 2025
Initiates: Outperform
Price Target: $65
Current: $27.59
Upside: +135.59%
argenx SE
Oct 31, 2025
Maintains: Outperform
Price Target: $775 → $910
Current: $811.45
Upside: +12.14%
Jasper Therapeutics
Sep 22, 2025
Maintains: Outperform
Price Target: $20 → $14
Current: $1.35
Upside: +937.04%
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $1.50
Upside: +233.33%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $2.51
Upside: +139.04%
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $18.50
Upside: +818.92%
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $5.68
Upside: +252.11%
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $272.74
Upside: -24.47%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $3.57
Upside: +516.25%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $1.82
Upside: +449.45%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $83.91
Upside: -28.49%